Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063104 | 0.82 | MEN1 (0.57) | ABCG2EGFR | |
| SCHEMBL411787 | 0.81 | MEN1 (0.74) | ABCG2 | |
| SCHEMBL20299017 | 0.79 | ABCG2 (0.86) | ABCG2 | |
| SCHEMBL14262819 | 0.79 | MEN1 (0.53) | ABCG2 | |
| SCHEMBL4628752 | 0.79 | MEN1 (0.47) | ABCG2 | |
| SCHEMBL4082133 | 0.78 | MEN1 (0.55) | ABCG2 | |
| SCHEMBL31399900 | 0.77 | ABCG2 (0.60) | ABCG2 | |
| SCHEMBL412084 | 0.76 | MEN1 (0.57) | ABCG2 | |
| SCHEMBL1058063 | 0.76 | MEN1 (0.52) | ABCG2 | |
| SCHEMBL4092472 | 0.75 | LMNA (0.67) | ABCG2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107959-B1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | claimed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | claimed |
| CN-1152867-C | Quinazoline derivatives as medicaments | �����ɷ� | 2004-06-09 | — | — | CN | claimed |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2003-04-10 | — | — | US | claimed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | claimed |
| US-20020161010-A1 | Quinazoline derivatives as medicaments | CHAKRAVARTY SARVAJIT (US) | 2002-10-31 | — | — | US | claimed |
| JP-2002523502-A | — | — | 2002-07-30 | — | — | JP | claimed |
| CN-1333757-A | Quinazoline derivatives as medicaments | SCIOS INC (US) | 2002-01-30 | — | — | CN | claimed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | claimed |
| EP-1107959-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | claimed |
| WO-2000012497-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2004004725-A2 | PHARMACEUTICAL COMPOSITIONS OF ANTICHOLINERGICS AND P38 KINASE INHIBITORS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | disclosed |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | disclosed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
| WO-2003084503-A2 | P38 KINASE INHIBITORS FOR TREATING MUCUS HYPERSECRETION_ | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161010-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | ABCG2 886/4885EGFR 377/4885 |
| US-20030225089-A1 | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | CHRM3, CHRM2, CHRNB1 | ABCG2 1169/4885EGFR 1703/4885 |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | ABCG2 1096/4885EGFR 537/4885 |
| US-20030069248-A1 | Quinazoline derivatives as medicaments | SMAD3, SMAD2, TGFBR1 | ABCG2 886/4885EGFR 377/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | ABCG2 3058/4885EGFR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.